21 October 2026 Melissa Kostopoulos ASX Supervision Level 45, South Tower Rialto 525 Collins Street Melbourne VIC 3000 (By email: listingssupervisionmelbourne@asx.com.au) Dear Melissa, AVECHO BIOTECHNOLOGY LIMITED (ASX: AVE) – PRICE QUERY In reference to your letter of 21 October 2026 regarding...
Response to ASX Price Query
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Avecho Biotechnology Limited has responded to an ASX price query regarding the recent trading activity of its securities, confirming no undisclosed information that could explain the trading changes. The company stated it is in compliance with the relevant listing rules and that its responses have been authorized by the Board. The ASX had noted a significant price change and increased trading volume, prompting their inquiry. Avecho's response was required promptly to avoid a potential trading halt or suspension of its securities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- Avecho to present at the Canaccord Drug and Device Confe
- Avecho to present at the ASX SMIDcaps Conference
- Avecho enters final stage of Phase III insomnia trial
- Appendix 4D and Half-year Financial Report
- Avecho strengthens BD capability with senior appointment
Later from Avecho Biotechnology
- Change of Chief Financial Officer
- September 2026 Quarterly Activities Report & Appendix 4C
- Avecho presents at BIO-Europe
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology